Association between XRCC3 rs861539 Polymorphism and the Risk of Ovarian Cancer: Meta-Analysis and Trial Sequential Analysis.

Tytuł:: Association between XRCC3 rs861539 Polymorphism and the Risk of Ovarian Cancer: Meta-Analysis and Trial Sequential Analysis.
Autorzy:: Hu S; Department of Obstetrics and Gynecology, Heilongjiang University of Chinese Medicine, Harbin 150040, China.
Jing Y; Department of Acupuncture and Moxibustion, Heilongjiang University of Chinese Medicine, Harbin 150040, China.
Liu F; Department of Obstetrics and Gynecology, Heilongjiang University of Chinese Medicine, Harbin 150040, China.
Han F; Department of Obstetrics and Gynecology, The First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin 150040, China.
Źródło:: BioMed research international [Biomed Res Int] 2022 Aug 08; Vol. 2022, pp. 3915402. Date of Electronic Publication: 2022 Aug 08 (Print Publication: 2022).
Typ publikacji:: Journal Article; Meta-Analysis; Review
Język:: English
Imprint Name(s):: Original Publication: New York, NY : Hindawi Pub. Co.
MeSH Terms:: Genetic Predisposition to Disease*/genetics
Ovarian Neoplasms*/genetics
Carcinoma, Ovarian Epithelial ; Case-Control Studies ; Female ; Humans ; Polymorphism, Single Nucleotide/genetics ; Risk Factors
References:: Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):2338-2342. (PMID: 31174441)
Tumour Biol. 2014 Mar;35(3):2711-5. (PMID: 24254304)
Clin Cancer Res. 2010 Apr 15;16(8):2344-51. (PMID: 20371688)
Arch Med Sci. 2021 Mar 18;18(1):1-10. (PMID: 35154519)
Mol Biol Rep. 2021 May;48(5):4209-4220. (PMID: 34097201)
Nat Rev Dis Primers. 2016 Aug 25;2:16061. (PMID: 27558151)
Anticancer Res. 2015 Jul;35(7):3893-9. (PMID: 26124335)
Genet Mol Res. 2014 Jan 28;13(1):636-48. (PMID: 24615029)
Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):319-23. (PMID: 15734952)
Int J Cancer. 2005 Nov 20;117(4):611-8. (PMID: 15924337)
J Clin Oncol. 2019 Sep 1;37(25):2257-2269. (PMID: 31050911)
Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2557-65. (PMID: 18086758)
PLoS One. 2022 Jan 21;17(1):e0259761. (PMID: 35061678)
Arch Gynecol Obstet. 2017 Sep;296(3):551-558. (PMID: 28676967)
J Exp Clin Cancer Res. 2013 Jan 04;32:1. (PMID: 23289442)
Oncotarget. 2016 Apr 12;7(15):19850-62. (PMID: 26918347)
Mol Genet Genomic Med. 2019 Oct;7(10):e00903. (PMID: 31454181)
Radiol Oncol. 2022 Apr 07;56(2):173-184. (PMID: 35390246)
Cancer Genet. 2021 Jun;254-255:11-17. (PMID: 33515810)
Nat Genet. 2001 Mar;27(3):247-54. (PMID: 11242102)
Urolithiasis. 2020 Oct;48(5):385-401. (PMID: 31515573)
Int J Mol Sci. 2022 Feb 01;23(3):. (PMID: 35163621)
Int J Clin Exp Med. 2013 Jun 26;6(6):438-43. (PMID: 23844267)
Oncol Lett. 2015 May;9(5):2425-2429. (PMID: 26137085)
Cell. 2017 Feb 9;168(4):644-656. (PMID: 28187286)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Cell Physiol Biochem. 2017;42(1):22-33. (PMID: 28490032)
PLoS One. 2011 Mar 29;6(3):e18202. (PMID: 21479231)
Carcinogenesis. 2001 Sep;22(9):1437-45. (PMID: 11532866)
BMC Med Genomics. 2021 Apr 30;14(1):117. (PMID: 33931047)
Proc Natl Acad Sci U S A. 2011 Nov 1;108(44):18032-7. (PMID: 22006311)
Gynecol Oncol. 2012 Feb;124(2):347-53. (PMID: 22264603)
Pathol Oncol Res. 2019 Oct;25(4):1607-1614. (PMID: 30712190)
CA Cancer J Clin. 2019 Jul;69(4):280-304. (PMID: 31099893)
JAMA Oncol. 2016 Apr;2(4):482-90. (PMID: 26720728)
Immunol Invest. 2021 Nov;50(8):987-1006. (PMID: 33390082)
Cancer Res. 2012 Nov 15;72(22):5675-82. (PMID: 23066035)
Int J Gen Med. 2022 May 13;15:4925-4936. (PMID: 35601003)
PLoS One. 2013 Aug 26;8(8):e68457. (PMID: 23990873)
Exp Mol Pathol. 2016 Apr;100(2):243-7. (PMID: 26801223)
BMJ. 2020 Nov 9;371:m3773. (PMID: 33168565)
Cancer Lett. 2018 Jun 28;424:119-126. (PMID: 29574277)
Entry Date(s):: Date Created: 20220818 Date Completed: 20220819 Latest Revision: 20220822
Update Code:: 20240105
PubMed Central ID:: PMC9377891
DOI:: 10.1155/2022/3915402
PMID:: 35978646
: Czasopismo naukowe

Pełny tekst

Background: Current studies on the relationship between XRCC3 rs861539 polymorphism and ovarian cancer risk have been inconsistent. Therefore, we performed a meta-analysis to explore their association.
Methods: Six electronic databases (PubMed, Embase, Web of Science, Cochrane Library, China National Knowledge Infrastructure, and China Wanfang Database) were searched for relevant studies published before December 2021. Meta-analysis, subgroup analysis, sensitivity analysis, and publication bias analysis were performed using Stata software 16.0. Trial sequential analysis (TSA) was performed using TSA 0.9.5.10 Beta software.
Results: A total of 12 studies were included in 9 literatures, comprising 4,634 cases of ovarian cancer and 7,381 controls. After Bonferroni correction, the meta-analysis showed an association between XRCC3 rs861539 polymorphism and ovarian cancer risk in the heterozygote model and the dominant model (GA vs. GG: OR = 0.88, 95%CI = 0.81-0.96, P = 0.003; GG vs. GA+AA: OR = 0.89, 95%CI = 0.82-0.96, P = 0.004). In an ethnically stratified subgroup analysis, XRCC3 rs861539 was shown to reduce the risk of ovarian cancer in Caucasian in the heterozygote model and the dominant model (GA vs. GG: OR = 0.88, 95%CI = 0.81-0.96, P = 0.004; GG vs. GA+AA: OR = 0.88, 95%CI = 0.81-0.96, P = 0.004). In the control source and detection method stratified subgroup analysis, hospital-based studies and PCR-RFLP-based studies were found to increase ovarian cancer risk (GG vs. AA: OR = 1.30, 95%CI = 1.05-1.62, P = 0.016; GG vs. AA: OR = 1.31, 95%CI = 1.06-1.62, P = 0.013).
Conclusion: This meta-analysis showed a significant association between XRCC3 rs861539 polymorphism and ovarian cancer risk, especially in Caucasians. Large-scale multicenter case-control studies in more different regions will be needed in the future.
Competing Interests: All authors declared that there is no competing interest.
(Copyright © 2022 Siya Hu et al.)

Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Informacja